APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infantile Spasms Therapeutics

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Selected research

Market Outlook & Growth Opportunities

Global Infantile Spasms Therapeutics Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchInfantile Spasms Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Infantile Spasms Therapeutics Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Infantile Spasms Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infantile Spasms Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Infantile Spasms Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.

In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.

Read the full market overview

This report provides an overview of the global Infantile Spasms Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Infantile Spasms Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Infantile Spasms Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Infantile Spasms Therapeutics market.

Infantile Spasms Therapeutics Segment by Company

Mallinckrodt

H. Lundbeck

Insys Therapeutics

Orphelia Pharma

Valerion Therapeutics

Catalyst Pharmaceuticals

Anavex Life Sciences

Retrophin

GW Pharmaceuticals

Infantile Spasms Therapeutics Segment by Type

Oral

Injection

Infantile Spasms Therapeutics Segment by Application

Hospital

Clinic

Other

Infantile Spasms Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Infantile Spasms Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Infantile Spasms Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Infantile Spasms Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Infantile Spasms Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Infantile Spasms Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Infantile Spasms Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infantile Spasms Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infantile Spasms Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infantile Spasms Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infantile Spasms Therapeutics industry.

Chapter 3: Detailed analysis of Infantile Spasms Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Infantile Spasms Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Infantile Spasms Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Infantile Spasms Therapeutics Industry Trends Table 2. Infantile Spasms Therapeutics Industry Drivers Table 3. Infantile Spasms Therapeutics Industry Opportunities and Challenges Table 4. Infantile Spasms Therapeutics Industry Restraints Table 5. Global Infantile Spasms Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Infantile Spasms Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Infantile Spasms Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Infantile Spasms Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Infantile Spasms Therapeutics Company, Product Type & Application Table 10. Global Infantile Spasms Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Infantile Spasms Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Global Infantile Spasms Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Infantile Spasms Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Infantile Spasms Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Infantile Spasms Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Infantile Spasms Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Infantile Spasms Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Infantile Spasms Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Infantile Spasms Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Infantile Spasms Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Infantile Spasms Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Infantile Spasms Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Infantile Spasms Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Infantile Spasms Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Infantile Spasms Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Infantile Spasms Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Infantile Spasms Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Infantile Spasms Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Infantile Spasms Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Infantile Spasms Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Infantile Spasms Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Mallinckrodt Company Information Table 40. Mallinckrodt Business Overview Table 41. Mallinckrodt Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Mallinckrodt Infantile Spasms Therapeutics Product Portfolio Table 43. Mallinckrodt Recent Development Table 44. H. Lundbeck Company Information Table 45. H. Lundbeck Business Overview Table 46. H. Lundbeck Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. H. Lundbeck Infantile Spasms Therapeutics Product Portfolio Table 48. H. Lundbeck Recent Development Table 49. Insys Therapeutics Company Information Table 50. Insys Therapeutics Business Overview Table 51. Insys Therapeutics Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio Table 53. Insys Therapeutics Recent Development Table 54. Orphelia Pharma Company Information Table 55. Orphelia Pharma Business Overview Table 56. Orphelia Pharma Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio Table 58. Orphelia Pharma Recent Development Table 59. Valerion Therapeutics Company Information Table 60. Valerion Therapeutics Business Overview Table 61. Valerion Therapeutics Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio Table 63. Valerion Therapeutics Recent Development Table 64. Catalyst Pharmaceuticals Company Information Table 65. Catalyst Pharmaceuticals Business Overview Table 66. Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio Table 68. Catalyst Pharmaceuticals Recent Development Table 69. Anavex Life Sciences Company Information Table 70. Anavex Life Sciences Business Overview Table 71. Anavex Life Sciences Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio Table 73. Anavex Life Sciences Recent Development Table 74. Retrophin Company Information Table 75. Retrophin Business Overview Table 76. Retrophin Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Retrophin Infantile Spasms Therapeutics Product Portfolio Table 78. Retrophin Recent Development Table 79. GW Pharmaceuticals Company Information Table 80. GW Pharmaceuticals Business Overview Table 81. GW Pharmaceuticals Infantile Spasms Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio Table 83. GW Pharmaceuticals Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Infantile Spasms Therapeutics Product Image Figure 2. Global Infantile Spasms Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infantile Spasms Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Infantile Spasms Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. Global Infantile Spasms Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Infantile Spasms Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Infantile Spasms Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Infantile Spasms Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Infantile Spasms Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Infantile Spasms Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Infantile Spasms Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Infantile Spasms Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Infantile Spasms Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Infantile Spasms Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Infantile Spasms Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Infantile Spasms Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Infantile Spasms Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Infantile Spasms Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Infantile Spasms Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Infantile Spasms Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Infantile Spasms Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Infantile Spasms Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Mallinckrodt
  • H. Lundbeck
  • Insys Therapeutics
  • Orphelia Pharma
  • Valerion Therapeutics
  • Catalyst Pharmaceuticals
  • Anavex Life Sciences
  • Retrophin
  • GW Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Infantile Spasms Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Infantile Spasms Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Infantile Spasms Therapeutics Market Dynamics
  1. 2.1 Infantile Spasms Therapeutics Industry Trends
  2. 2.2 Infantile Spasms Therapeutics Industry Drivers
  3. 2.3 Infantile Spasms Therapeutics Industry Opportunities and Challenges
  4. 2.4 Infantile Spasms Therapeutics Industry Restraints
3 Infantile Spasms Therapeutics Market by Company
  1. 3.1 Global Infantile Spasms Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Infantile Spasms Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Infantile Spasms Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Infantile Spasms Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Infantile Spasms Therapeutics Company Product Type and Application
  6. 3.6 Global Infantile Spasms Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Infantile Spasms Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Infantile Spasms Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Infantile Spasms Therapeutics Market by Type
  1. 4.1 Infantile Spasms Therapeutics Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Infantile Spasms Therapeutics Sales Value by Type
  5. 4.2.1 Global Infantile Spasms Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Infantile Spasms Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Infantile Spasms Therapeutics Sales Value Share by Type (2021-2032)
5 Infantile Spasms Therapeutics Market by Application
  1. 5.1 Infantile Spasms Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Infantile Spasms Therapeutics Sales Value by Application
  6. 5.2.1 Global Infantile Spasms Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Infantile Spasms Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Infantile Spasms Therapeutics Sales Value Share by Application (2021-2032)
6 Infantile Spasms Therapeutics Regional Value Analysis
  1. 6.1 Global Infantile Spasms Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Infantile Spasms Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Infantile Spasms Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Infantile Spasms Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Infantile Spasms Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Infantile Spasms Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Infantile Spasms Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Infantile Spasms Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Infantile Spasms Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Infantile Spasms Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Infantile Spasms Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Infantile Spasms Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Infantile Spasms Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Infantile Spasms Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Infantile Spasms Therapeutics Country-level Value Analysis
  1. 7.1 Global Infantile Spasms Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Infantile Spasms Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Infantile Spasms Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Infantile Spasms Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Infantile Spasms Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Infantile Spasms Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Infantile Spasms Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Mallinckrodt
  2. 8.1.1 Mallinckrodt Company Information
  3. 8.1.2 Mallinckrodt Business Overview
  4. 8.1.3 Mallinckrodt Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Mallinckrodt Infantile Spasms Therapeutics Product Portfolio
  6. 8.1.5 Mallinckrodt Recent Developments
  7. 8.2 H. Lundbeck
  8. 8.2.1 H. Lundbeck Company Information
  9. 8.2.2 H. Lundbeck Business Overview
  10. 8.2.3 H. Lundbeck Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 H. Lundbeck Infantile Spasms Therapeutics Product Portfolio
  12. 8.2.5 H. Lundbeck Recent Developments
  13. 8.3 Insys Therapeutics
  14. 8.3.1 Insys Therapeutics Company Information
  15. 8.3.2 Insys Therapeutics Business Overview
  16. 8.3.3 Insys Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio
  18. 8.3.5 Insys Therapeutics Recent Developments
  19. 8.4 Orphelia Pharma
  20. 8.4.1 Orphelia Pharma Company Information
  21. 8.4.2 Orphelia Pharma Business Overview
  22. 8.4.3 Orphelia Pharma Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio
  24. 8.4.5 Orphelia Pharma Recent Developments
  25. 8.5 Valerion Therapeutics
  26. 8.5.1 Valerion Therapeutics Company Information
  27. 8.5.2 Valerion Therapeutics Business Overview
  28. 8.5.3 Valerion Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio
  30. 8.5.5 Valerion Therapeutics Recent Developments
  31. 8.6 Catalyst Pharmaceuticals
  32. 8.6.1 Catalyst Pharmaceuticals Company Information
  33. 8.6.2 Catalyst Pharmaceuticals Business Overview
  34. 8.6.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
  36. 8.6.5 Catalyst Pharmaceuticals Recent Developments
  37. 8.7 Anavex Life Sciences
  38. 8.7.1 Anavex Life Sciences Company Information
  39. 8.7.2 Anavex Life Sciences Business Overview
  40. 8.7.3 Anavex Life Sciences Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio
  42. 8.7.5 Anavex Life Sciences Recent Developments
  43. 8.8 Retrophin
  44. 8.8.1 Retrophin Company Information
  45. 8.8.2 Retrophin Business Overview
  46. 8.8.3 Retrophin Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Retrophin Infantile Spasms Therapeutics Product Portfolio
  48. 8.8.5 Retrophin Recent Developments
  49. 8.9 GW Pharmaceuticals
  50. 8.9.1 GW Pharmaceuticals Company Information
  51. 8.9.2 GW Pharmaceuticals Business Overview
  52. 8.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
  54. 8.9.5 GW Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst